112 related articles for article (PubMed ID: 10706192)
1. Interethnic differences of drug-metabolizing enzymes.
Gaedigk A
Int J Clin Pharmacol Ther; 2000 Feb; 38(2):61-8. PubMed ID: 10706192
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics and psychopharmacotherapy.
Poolsup N; Li Wan Po A; Knight TL
J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.
Masimirembwa CM; Hasler JA
Brain Res Bull; 1997; 44(5):561-71. PubMed ID: 9365799
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics: role in modifying drug dosage regimens.
Mah JT; Wong JY; Lee EJ
Ann Acad Med Singap; 2000 Sep; 29(5):628-32. PubMed ID: 11126699
[TBL] [Abstract][Full Text] [Related]
5. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
Ford GA; Wood SM; Daly AK
Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
[TBL] [Abstract][Full Text] [Related]
7. [Genetic polymorphism of drug metabolizing enzymes].
Yokoi T; Kamataki T
Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
[No Abstract] [Full Text] [Related]
8. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
9. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia.
Roddam PL; Rollinson S; Kane E; Roman E; Moorman A; Cartwright R; Morgan GJ
Pharmacogenetics; 2000 Oct; 10(7):605-15. PubMed ID: 11037802
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of cytochromes P450.
Hasler JA
Mol Aspects Med; 1999; 20(1-2):12-24, 25-137. PubMed ID: 10575648
[No Abstract] [Full Text] [Related]
11. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.
Rogers JF; Nafziger AN; Bertino JS
Am J Med; 2002 Dec; 113(9):746-50. PubMed ID: 12517365
[TBL] [Abstract][Full Text] [Related]
13. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
15. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations.
Gaedigk A; Tyndale RF; Jurima-Romet M; Sellers EM; Grant DM; Leeder JS
Pharmacogenetics; 1998 Aug; 8(4):305-13. PubMed ID: 9731717
[TBL] [Abstract][Full Text] [Related]
16. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
18. How to correctly calculate the proportions of the heterozygotes and homozygotes in the extensive metabolizers of a certain drug-metabolizing enzyme in an ethnic or racial population?
Xie HG
Clin Pharmacol Ther; 1998 Nov; 64(5):575. PubMed ID: 9834051
[No Abstract] [Full Text] [Related]
19. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
de Leon J
J Clin Psychopharmacol; 2007 Jun; 27(3):241-5. PubMed ID: 17502769
[No Abstract] [Full Text] [Related]
20. A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment.
Johnson M; Markham-Abedi C; Susce MT; Murray-Carmichael E; McCollum S; de Leon J
CNS Spectr; 2006 Oct; 11(10):757-60. PubMed ID: 17008819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
